Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Warm Autoimmune Hemolytic Anemia (wAIHA): full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Warm Autoimmune Hemolytic Anemia (wAIHA): 2 US clinical trials tracked, none currently recruiting.
Warm Autoimmune Hemolytic Anemia (wAIHA) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 1 of these trials.
Enrollment posture brief
Registry condition warm-autoimmune-hemolytic-anemia-waiha
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Warm Autoimmune Hemolytic Anemia (wAIHA) has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Warm Autoimmune Hemolytic Anemia (wAIHA) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Warm Autoimmune Hemolytic Anemia (wAIHA) is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Novartis Pharmaceuticals
NCT05648968
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
Sanofi
NCT05002777
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Warm Autoimmune Hemolytic Anemia (wAIHA) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Warm Autoimmune Hemolytic Anemia (wAIHA) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Warm Autoimmune Hemolytic Anemia (wAIHA) page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Warm Autoimmune Hemolytic Anemia (wAIHA) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sanofi sponsors the most Warm Autoimmune Hemolytic Anemia (wAIHA) trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Warm Autoimmune Hemolytic Anemia (wAIHA) condition card totals 2 registered trials; most-linked intervention Ianalumab; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.